Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City

DURHAM, NC / ACCESSWIRE / March 20, 2017 / Heat Biologics, Inc. (NASDAQ: HTBX, "Heat"), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced today that it will be presenting at this year's The MicroCap Conference on April 4th at 11:30 a.m. in New York City at the Essex House.

About Heat Biologics, Inc.

Heat Biologics, Inc. (NASDAQ: HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient's immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).

Heat's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.

For more information, please visit www.heatbio.com.

Contact:

Jennifer Almond
Investor and Media Relations
919-240-7133
Investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

Released March 20, 2017